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Abstract
Background: Femoroacetabular impingement syndrome (FAI), a hip disorder affecting active young adults, is
believed to be a leading cause of hip osteoarthritis (OA). Current management approaches for FAI include
arthroscopic hip surgery and physiotherapy-led non-surgical care; however, there is a paucity of clinical trial
evidence comparing these approaches. In particular, it is unknown whether these management approaches
modify the future risk of developing hip OA. The primary objective of this randomised controlled trial is to
determine if participants with FAI who undergo hip arthroscopy have greater improvements in hip cartilage
health, as demonstrated by changes in delayed gadolinium-enhanced magnetic resonance imaging (MRI) of
cartilage (dGEMRIC) index between baseline and 12 months, compared to those who undergo physiotherapy-led
non-surgical management.
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Methods: This is a pragmatic, multi-centre, two-arm superiority randomised controlled trial comparing hip arthroscopy
to physiotherapy-led management for FAI. A total of 140 participants with FAI will be recruited from the clinics of
participating orthopaedic surgeons, and randomly allocated to receive either surgery or physiotherapy-led non-surgical
care. The surgical intervention involves arthroscopic FAI surgery from one of eight orthopaedic surgeons specialising in
this field, located in three different Australian cities. The physiotherapy-led non-surgical management is an individualised
physiotherapy program, named Personalised Hip Therapy (PHT), developed by a panel to represent the best non-
operative care for FAI. It entails at least six individual physiotherapy sessions over 12 weeks, and up to ten sessions over
six months, provided by experienced musculoskeletal physiotherapists trained to deliver the PHT program. The primary
outcome measure is the change in dGEMRIC score of a ROI containing both acetabular and femoral head cartilages at
the chondrolabral transitional zone of the mid-sagittal plane between baseline and 12 months. Secondary outcomes
include patient-reported outcomes and several structural and biomechanical measures relevant to the pathogenesis of
FAI and development of hip OA. Interventions will be compared by intention-to-treat analysis.
Discussion: The findings will help determine whether hip arthroscopy or an individualised physiotherapy program is
superior for the management of FAI, including for the prevention of hip OA.
Trial registration: Australia New Zealand Clinical Trials Registry reference: ACTRN12615001177549. Trial registered 2/11/
2015 (retrospectively registered).
Keywords: Arthroscopy, dGEMRIC, Femoroacetabular impingement syndrome, Fai, Hip, Orthopaedic, Osteoarthritis,
Physiotherapy, Surgery
Background
FAI syndrome (FAI) is a motion-related clinical disorder
of the hip with a triad of symptoms, clinical signs, and im-
aging findings [1]. It represents symptomatic premature
contact between the proximal femur and acetabulum.
Two morphologic patterns of FAI have been described:
cam type, where the femoral head is aspheric due to a
thickened femoral head-neck junction; and pincer type,
where the acetabular rim extends beyond its normal depth
to over-cover the femoral head [2]. Both cam and pincer
type morphology are associated with the repetitive abut-
ment of the proximal femur against the acetabular rim,
applying shear forces to the acetabular labrum and/or car-
tilage, which is believed to lead to hip osteoarthritis (OA)
[3–5]. The evidence linking FAI to the development of hip
OA is rapidly expanding, such that FAI is now believed to
be a precursor to what was previously described as pri-
mary or idiopathic hip OA [2, 6–11].
Hip OA is associated with reduced quality of life and
high healthcare costs [12]. Effective treatments for FAI
may reduce the risk of hip OA as well as alleviating symp-
toms of the syndrome itself. Current popular management
approaches for FAI include surgery, most commonly in
the form of hip arthroscopy, and physiotherapy-led non-
surgical care. There is a notable lack of high-quality re-
search comparing outcomes between these two manage-
ment approaches [13, 14]. In particular, it is unknown
whether either of these approaches modifies the risk of fu-
ture hip OA development.
Ganz and colleagues first described the pathomechan-
ism of FAI, as well as an open approach to surgically
correct the associated bony abnormalities, at the turn of
the twenty-first century [2, 4, 5]. Over the last decade,
arthroscopic hip surgery for FAI has been performed at
a growing rate worldwide [15, 16]. Arthroscopic FAI
surgery involves resection of the cam and/or pincer
morphology, and usually involves surgical repair of con-
comitant FAI-associated soft tissue pathology, such as
acetabular labral tears and chondral defects. Case series
have reported positive outcomes from hip arthroscopy
for FAI [17–20], however, no randomised controlled tri-
als (RCTs) have yet been completed that compare hip
arthroscopy to other interventions or to sham surgery
[13]. As such, the effectiveness of hip arthroscopy for
FAI remains unknown.
Non-surgical management of FAI has encompassed
various methods, the mainstay of which has been
physiotherapy-led exercise rehabilitation, oftentimes ac-
companied by anti-inflammatories or corticosteroid in-
jections [14, 21]. Central aspects of physiotherapy-led
management typically include a progressive physiotherapist
supervised rehabilitation exercise program, education about
FAI, and pain relief, particularly anti-inflammatory medica-
tions and sometimes intra-articular corticosteroid injections
[21]. The focus of rehabilitation exercise programs is the
restoration of hip muscle function and strength, to improve
control of the femoral head, thereby reducing hip impinge-
ment in positions of substantial hip flexion, adduction and
internal rotation [22–24]. As with surgery, there is a paucity
of RCT evidence to determine whether physiotherapy-led
non-surgical care is efficacious in treating FAI, and how its
efficacy compares to other management approaches [14].
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Rationale
There is a need for RCTs comparing arthroscopic hip
surgery to physiotherapy-led non-surgical care for the
treatment of FAI [13]. Given the probable causative role
that FAI plays in hip OA, an important criterion by
which each treatment must be evaluated is its effect on
risk of future hip OA. A major problem encountered in
investigating such an outcome is that the onset of OA,
and thus a meaningful comparison between treatment
groups, takes several decades to occur. A different ap-
proach is needed to direct current clinical practice. This
RCT will measure several structural and biomechanical
outcomes relevant to the pathogenesis of hip OA, with
the aim of determining whether hip arthroscopy and
physiotherapy-led non-surgical care differ in their effect
on risk of future hip OA. This RCT is being conducted
in collaboration with the UK FASHIoN trial (Trial Regis-
tration number: ISRCTN64081839) [25], which shares
identical physiotherapy and surgical protocols to the
Australian FASHIoN trial. Whereas the UK FASHIoN
trial is focused on comparing patient-reported outcomes
between the two interventions, the Australian FASHIoN
trial is primarily investigating mechanistic outcomes.
Objectives of the Australian FASHIoN trial
Primary objective
To compare 12-month changes in hip cartilage health
between treatment groups, as demonstrated by changes
in the average dGEMRIC score for a region of interest
(ROI) including both acetabular and femoral head cartil-
age cartilages at the chondrolabral transitional zone.
Secondary objectives
 Compare 12-month change in hip cartilage health
between treatment groups, as demonstrated by
changes in the dGEMRIC scores of separate acetab-
ular and femoral head cartilage ROIs at the chon-
drolabral transitional zone.
 Compare 12-month change in hip MRI and plain X-
ray features between treatment groups, using the
Hip Osteoarthritis MRI Scoring System (HOAMS)
and Hip2Norm software, respectively.
 Compare 12-month change in hip joint three-
dimensional stresses and strains during walking and
various functional tasks between treatment groups.
 Determine if changes in hip joint structure after
12 months are related to symptomatic
improvements.
 Compare 12-month change in hip muscle activation
patterns and co-contraction patterns between treat-
ment groups.
 Compare 12-month change in hip joint motion and
moments in gait between treatment groups.
 Compare 12-month change in hip isometric muscle
strength between treatment groups.
 Compare 12-month change in hip joint contact
forces between treatment groups.
The objectives of the UK FASHIoN trial [25] are sec-
ondary objectives of our trial, and include:
 Compare changes in patient-reported hip-specific
quality of life after 12 months, as measured by the
international Hip Outcome Tool-33 (iHOT-33).
 Compare changes between treatment groups in
general health status and health-related quality of
life after 12 months, as measured by the Short
Form-12 (SF-12).
 Compare differences between treatment groups in
patient satisfaction with treatment and outcome
after 12 months.
 Compare differences between treatment groups in
the number and severity of adverse events after
treatment after 12 months.
 Compare differences between treatment groups in
the need for further surgical procedures up to three
years.
 Compare the cost-effectiveness of hip arthroscopy
for FAI with non-surgical care, within the trial, and
estimated for a patient’s lifetime.
 Measure fidelity of delivery of interventions.
Methods/design
Trial design
This trial will be conducted in compliance with the
Australian National Health and Medical Research Council
(NHMRC) National Statement on Ethical Conduct in
Human Research (2007), the Note for Guidance on Good
Clinical Practice (CPMP/ICH-135/95), and the conditions
of the ethics approval granted by St Vincent’s Hospital
Human Research Ethics Committee (HREC/14/SVH/343).
Results for this trial will be reported in accordance with
the CONSORT statement.
The protocol for Australian FASHIoN is similar to that
for the parallel UK FASHIoN trial [25], and benefits from
the feasibility study performed for the UK trial [26, 27] and
from collaboration between the Australian and UK research
groups. Inclusion and exclusion criteria, and intervention
specifications are identical. Patient-reported outcomes
and timing of those outcome assessments are the same.
The key differences are the mechanistic structural and
biomechanical outcomes investigated in the Australian
FASHIoN trial.
The Australian FASHIoN trial is a pragmatic, assessor-
and statistician-blinded, two-arm superiority RCT with
1:1 allocation ratio. 140 participants will be recruited from
the private and/or public clinics of eight orthopaedic
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surgeons, spread across three regions in Australia. Recruit-
ment and/or arthroscopic surgery will be carried out at the
following hospital sites; in New South Wales (NSW): Mater
Hospital, Norwest Hospital, Sydney Adventist Hospital, St
George Private Hospital, St Luke’s Hospital, Sutherland
Hospital; in Victoria (VIC): Maroondah Hospital, St Vin-
cent’s Private Hospital (East Melbourne), Western Health;
and in the Australian Capital Territory (ACT): Canberra
Hospital, Calvary Hospital. The PHT program will be ad-
ministered at various private physiotherapy clinics located
throughout NSW, VIC and ACT.
PHT will commence after treatment allocation and con-
tinue for a maximum of six months, with six compulsory
physiotherapy sessions within the first 12 weeks and up to
ten sessions over the first six months if needed by the par-
ticipant. Arthroscopic hip surgery will occur as soon as
practicable and no more than 18 weeks after treatment al-
location. Post-operative rehabilitation will not be standar-
dised, and will occur as per each participating orthopaedic
surgeon’s usual rehabilitation protocol. The primary out-
come will be measured 12 months post-randomisation.
For further details, see Trial Design flow chart (see Fig. 1).
Eligibility criteria
Participants will be eligible for participation in the trial if
they meet all of the following inclusion criteria and none
of the exclusion criteria.
Inclusion criteria
 Age > 16 years;
 Symptoms of hip pain that may include clicking,
catching, and/or giving way;
 Radiological signs of FAI, defined as:
 Alpha angle >55° for cam morphology [28]; and/or
 Lateral centre edge angle >40° or other
radiographic signs of pincer morphology, such as
positive cross-over sign [29].
Fig. 1 Trial Design Flow Chart
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 Treating surgeon believes the patient would benefit
from arthroscopic FAI surgery;
 Willing and able to give written informed consent
and participate fully in the interventions and follow-
up procedures.
Exclusion criteria
 Evidence of pre-existing hip OA in the hip being
considered for treatment in the study, defined as
Tonnis grade > 1 or more than 2 mm loss of super-
ior joint space width on anteroposterior pelvic
radiograph [20, 30];
 Previous significant hip pathology such as Perthes’
disease, slipped upper femoral epiphysis or avascular
necrosis;
 Previous hip injury such as acetabular fracture, hip
dislocation or femoral neck fracture;
 Previous shape changing surgery (open or
arthroscopic) to the hip being considered for
treatment;
 Inability to have MRI with contrast (e.g. due to renal
impairment, pregnancy, or breast-feeding).
Recruitment
Eligible patients will be recruited via the private practice
and/or public hospital clinics of eight orthopaedic sur-
geons, located in three different Australian cities, specia-
lising in arthroscopic hip surgery. Orthopaedic surgeons
will assess patients as usual, taking a history, performing
a physical examination, and obtaining further investiga-
tions as appropriate. Patients in whom a diagnosis of
FAI is made, and who meet the eligibility criteria, will be
offered a trial information consultation with a trained
clinical researcher and be invited to provide their in-
formed written consent to join the FASHIoN study. Pa-
tients with bilateral FAI will be asked to nominate their
most symptomatic hip satisfying the eligibility criteria
for inclusion in the study.
Randomisation
Randomisation to either arthroscopic hip surgery or
non-surgical physiotherapy-led care will occur in a 1:1
ratio using a computer-generated minimisation sequence
(adaptive stratified sampling) with study site and type of
FAI (cam, pincer or mixed FAI) as factors. Allocation
concealment will be preserved by having randomisation
codes held by an external biostatistician. At randomisa-
tion, participants will be given a study ID that will be
used on all trial documentation.
Blinding
Neither participants, nor treating surgeons/physiothera-
pists, can be blinded to treatment allocation in this
study. The treating surgeons and physiotherapists will
take no part in outcome assessment for the trial. Im-
aging and biomechanical analyses will be performed in a
blinded fashion. The patient reported outcome data will
be collected via online surveys and postal questionnaires,
which will be entered onto the central trial database by a
research assistant blinded to treatment allocation.
Interventions
Arthroscopic hip surgery
Arthroscopic surgery will be standardised and performed
by one of eight orthopaedic surgeons experienced in
arthroscopic hip surgery for FAI. Participants will access
surgery through either the public healthcare system, with
no out-of-pocket cost, or through the private healthcare
system, typically associated with additional out-of-pocket
costs. After giving written informed consent for the pro-
cedure, patients will undergo routine preoperative care,
including an anaesthetic consultation to assess surgical
fitness. Surgery will be performed under general anaes-
thesia in either a lateral or supine position. Arthroscopic
portals will be established in the central and peripheral
compartment under radiographic guidance, according to
each surgeon’s usual practice. Shape abnormalities and
consequent labral and cartilage pathologies will be treated.
Bony resection at the acetabular rim and the head-neck
junction will be assessed by intraoperative image intensi-
fier radiograph and/or satisfactory impingement free range
of movement of the hip. Osteo-integrative anchors will be
used during the surgical procedure to avoid issues with
post-operative MRI quality and dGEMRIC accuracy.
Patients will be discharged from the hospital when
they can walk safely with crutches (usually within 24 h).
A protocol for post-operative rehabilitation will not be
specified, although all patients will be instructed to fol-
low the usual post-operative rehabilitation protocol rec-
ommended by their surgeon. Physiotherapists providing
post-operative rehabilitation care will be distinct from
those providing the physiotherapy-led non-surgical care
in this trial to avoid contamination between groups.
To assess the fidelity of the treatment received to the
prescribed surgical protocol, an international panel of
surgeons specialised in hip arthroscopy will review a
random sample of the participants treated by each of the
study surgeons. Operation notes, intraoperative images,
and postoperative MRI scans will be used to evaluate the
adequacy of the surgical intervention.
Physiotherapy-led non-surgical care
The physiotherapy-led non-surgical care provided to par-
ticipants through this trial is called Personalised Hip Ther-
apy (PHT) [21]. It was designed to represent a consensus
on the best non-surgical care for FAI by an international
panel of physiotherapists, physicians, and surgeons. PHT
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program will be provided at no cost to participants and
will be delivered by experienced musculoskeletal physio-
therapists trained in its delivery. Physiotherapists deliver-
ing the PHT program will take part in a one-day training
course explaining the rationale for the FASHIoN trial and
the PHT program, and instruction on how to record data
related to fidelity of the intervention delivery. Participants
will undergo a minimum of six PHT sessions during the
first 12 weeks of the study, commencing as soon after ran-
domisation as is practicable. If needed, participants may
have additional PHT sessions between 12 weeks and six
months, with a maximum of ten sessions provided by the
study. Further physiotherapy treatment beyond the ten
sessions provided by the PHT physiotherapist will not
form part of the PHT protocol and will be recorded as a
co-intervention.
The PHT program encompasses a multi-faceted ap-
proach, beginning with an assessment of the patient’s
pain, function and hip range of motion. The core aspects
of the program include (i) an individualised and progres-
sive exercise programme supervised by a physiotherapist,
(ii) education as to the condition and its management,
and (iii) advice regarding pain relief which may include
referral to the participants’ General Practitioner, or if ne-
cessary referral for an ultrasound-guided intra-articular
steroid injection to enable participants to engage in the
exercise programme where pain would otherwise pre-
vent them from doing so. The PHT program represents
a structured and individualised approach to FAI manage-
ment. Physiotherapists will be provided with a set of rec-
ommended exercises as part of the program, from which
they will prescribe appropriate exercises for each partici-
pant’s stage of rehabilitation. Participants will be given a
logbook to record the exercises they complete at home.
Data from the logbook will not be collected by re-
searchers, but will be used to enhance physiotherapist-
patient communication and facilitate the development of
strategies to maximise patient adherence to the pre-
scribed exercises.
The key features of the exercise programme are indi-
vidualisation, progression and supervision; thus, evi-
dence of these features will be sought from individual
participant PHT case report forms (CRFs). A randomly
selected sample of CRFs for participants treated by each
of the PHT physiotherapists will be assessed members of
the panel that developed the PHT protocol to assess
treatment fidelity.
Outcomes
The primary outcome measure for analysis will be the 12-
month change in the average T1 relaxation time, assessed
with dGEMRIC, for a ROI comprising both acetabular
and femoral head cartilages at the chondrolabral transi-
tional zone of the mid-sagittal plane. The 12-month
change in separate acetabular and femoral head cartilage
ROIs at the chondrolabral transitional zone will be ana-
lysed as a secondary outcome. In addition, the 12-month
change in standardised dGEMRIC z-scores for the acetab-
ular and femoral head cartilage ROIs at the chondrolabral
junction will be analysed, using the central femoral cartil-
age ROI as an internal control [31, 32]. The dGEMRIC
technique has been proven reliable for quantification and
detection of changes in the glycosaminoglycan (GAG)
content of the hip joint cartilage [33–36]. Since the loss of
GAG in cartilage is an early OA-related change [37],
dGEMRIC enables the likelihood of future OA develop-
ment to be compared between treatment methods after a
relatively short period. Further detail regarding the
dGEMRIC outcome measurements and analyses is in-
cluded below.
Other secondary outcomes will include hip joint struc-
tural change between baseline and 12 months as demon-
strated by the semi-quantitative whole Hip OA MRI
Score (HOAMS), and by plain radiographic and MRI
measures of alpha angle, acetabular depth, femoral and
acetabular version; change between baseline and
12 months in hip joint biomechanics during gait and
functional tasks as measured by external hip joint mo-
tion and moments, muscle activation and co-contraction
patterns, net hip joint contact forces in localised regions
of cartilage, and regional cartilage stresses and strains;
cost-effectiveness of the interventions as measured by
the modified World Health Organisation Health and
Work Performance Questionnaire (WHO HPQ) [38];
changes in participant symptoms and quality of life as
measured by the international Hip Outcome Tool-33
(iHOT-33) [39], the Hip disability and Osteoarthritis
Outcome Score (HOOS) [40–42], EQ-5D [43], and the
12-Item Short Form Health Survey (SF-12) [44]; patient
perceived overall improvement following intervention
measured using a Global Improvement Scale (GIS); and
patient satisfaction with care and treatment results mea-
sured on a five-point Likert scale. Procedures for meas-
urement and analysis of each of the secondary outcomes
is described in greater detail below. The table of data
collection and time points (see Table 1) summarises the
timeline for each of the study procedures.
MRI
All participants will undergo an MRI scan at baseline
and 12 months, performed on one of three 3 T MRI
scanners using a phased array coil on a Siemens Prisma
(Melbourne), Siemens Skyra (Sydney), or Phillips Ingenia
(Canberra). Participants will be scanned on the same
scanner at baseline and 12 months. Participants will re-
ceive an intravenous injection of the contrast agent;
0.2 mmol/kg bodyweight of Dotarem (Gd-DOTA; Guer-
bet, Cedex, France) or Magnevist (Gd-DTPA; Berlex
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Labs, Wayne, NJ). Following injection of contrast agent,
participants will walk for 15 min, after which MRI scan-
ning will occur.
The following MRI sequences, all using a surface coil, will
be part of the protocol: coronal and axial fat-suppressed
T1-weighted spin-echo sequence (TR 600 ms, TE 7.9 ms,
slice thickness/slice gap 3.0 mm/0.3 mm, echo train length
3, field of view (FOV) 18 × 18 cm, matrix size 256 × 256,
number of signal averages 1, number of slices 24), coronal
and sagittal proton density-weighted fat-suppressed fast
spin-echo sequence (TR 2230 & 2770 ms, TE 29 & 36 ms,
slice thickness/slice gap 3.0 mm/0.3 mm, echo train length
7 & 9, FOV 18 × 18 cm, matrix size 256 × 256, number of
signal averages 2), a sagittal 3D T2-weighted true fast im-
aging with steady-state precession sequence (TR 10.2 ms,
TE 4.3 ms, slice thickness 0.63 mm, FOV 16 × 16 cm,
matrix size 256 × 256, number of signal averages 1), an
axial fat-suppressed T1-weighted spin-echo sequence of the
pelvis covering the hip joints (TR 500 ms, TE 8.9 ms, slice
thickness/slice gap 3.0 mm/0.9 mm, echo train length 3,
FOV 36 × 36 cm, matrix size 256 × 256, number of signal
averages 1), an axial fat-suppressed T1-weighted spin-echo
sequence of the knees (TR 550 ms, TE 11 ms, slice thick-
ness/slice gap 5.0 mm/1.5 mm, echo train length 4, FOV
32 × 32, number of signal averages 2), an axial fat sup-
pressed T1-weighted spin-echo sequence of the ankles at
the Melbourne site only (TR 470 ms, TE 12 ms, slice thick-
ness / slice gap 5.0/1.5 mm, echo train length 3, FOV
36 × 36 cm, matrix size 320 × 320, number of signal aver-
ages 1), and the dGEMRIC sequences (spin-echo inversion
recovery with fat suppression; sagittal orientation, TR
2340 ms, TE 15 ms, slice thickness/slice gap 3.0 mm/
3.0 mm, echo train length 11, FOV 16 × 16 cm, matrix size
256 × 256, number of signal averages 1; 6 IR delays at 50,
100, 200, 400, 800, and 1600 ms). Acquisition of dGEMRIC
sequences will occur in the 45–60-min time window
(following injection), consistent with previously performed
dGEMRIC protocols. The total time for the MRI examin-
ation including patient positioning will be approximately
45 min, excluding walking and contrast injection.
MRI sequences were chosen to enable scoring with the
HOAMS, a validated and reliable semi-quantitative whole
hip osteoarthritis MRI scoring system [45]. Changes in
HOAMS scores between baseline and 12 months will be
reported. The MRI measures of FAI morphology will be
reported both at baseline and 12 months, including alpha
angle, acetabular version and femoral version. Alpha angle
will be measured in 30-degree intervals from the ‘superior’
to ‘anterior’ locations, with the largest alpha angle and its
location to be reported. Acetabular version will be mea-
sured using the T1-weighted axial hips sequence and will
be reported at 1 cm from the roof of the acetabulum and
at the centre of the acetabulum. Femoral version will be
measured on the T1-weighted axial hip and knee se-
quences and will be defined as the difference between the
angle made by the long axis of the femoral neck and the
angle made by the posterior distal femoral condyles, as de-
scribed previously [46].
dGEMRIC
Following MRI acquisition, dGEMRIC analysis will be
carried out using a methodology closely based on that
validated in previously published studies [47]. Acetabu-
lar and femoral head cartilage ROIs will be defined for
three mid-sagittal plane slices at the chondrolabral
transitional zone, reaching approximately 3 to 6 mm to-
ward the acetabular fossa in each hip. Accurate posi-
tioning of the mid-sagittal plane was ensured using a
three-dimensional view of the hip volume in Osirix
(version 8, Geneva, Switzerland [48]; see Fig. 2). This
cartilage subregion has been chosen for analysis due to
its relevance in the pathogenesis of FAI [4, 49]. Care
Table 1 Table of data collection and time points
Time points: Baseline 6 months 12 months 24 & 36 months
Data
collection:
Demographic information
Physical activity (modified UCLA Activity
Scale)
MRI scan
dGEMRIC scan
Plain radiography
3D gait analysis
EMG-informed NMS and FEM models
iHOT-33
HOOS
SF-12
EQ-5D
WHO HPQ (modified)
iHOT-33
HOOS
GIS
SF-12
EQ-5D
WHO HPQ
(modified)
MRI scan
dGEMRIC scan
Plain radiography
3D gait analysis
EMG-informed NMS and FEM
models,
iHOT-33
HOOS
GIS
SF-12
EQ-5D
Patient satisfaction
Resource utilization
Adverse events
WHO HPQ (modified)
Further procedures
questionnaire
dGEMRIC = delayed gadolinium-enhanced magnetic resonance imaging of cartilage, EMG-informed NMS and FEM models = electromyography-informed
neuromusculosketal and finite element models, iHOT-33 = international Hip Outcome Tool-33, HOOS = Hip disability and Osteoarthritis Outcome Score, SF-
12 = Short-Form 12, European Quality of life-5 dimensions, WHO HPQ = World Health Organisation Health and Work Performance Questionnaire, GIS = Global
Improvement Score
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will be taken to define ROIs including only acetabular
and femoral head cartilage separately, while excluding
labrum and bone. The mean change in T1 values be-
tween baseline and 12 months for these ROIs will be
reported.
We will also calculate z-scores for the acetabular and
femoral cartilage ROIs at the chondrolabral junction,
using the standardised dGEMRIC method proposed by
Lattanzi et al. [31, 32]. Standardised dGEMRIC uses the
healthy central femoral head cartilage as an internal con-
trol to which other cartilage ROIs can be compared, by
transforming the T1 values (x) to standard scores (z)
using z = (x - μ) / σ, where μ and σ are the mean and
standard deviation, respectively, of T1 values within the
central femoral head cartilage ROI. Standardised dGEM-
RIC enables better comparison of local cartilage damage
between different individuals as it removes the effect of
individual-level factors affecting T1 values such as age,
sex, BMI, and differences in gadolinium diffusion and
transport rates through cartilage [31]. Standardised
dGEMRIC z-scores will be reported at baseline and
12 months for acetabular and femoral ROIs at the chon-
drolabral junction, with a central femoral cartilage ROI
to be used as an internal control. By measuring and
reporting the change in standardised dGEMRIC scores be-
tween baseline and 12 months, we will mitigate the effect
that surgical trauma has been posited to have in reducing
cartilage T1 values globally for a period of time following
surgery [50, 51]. Change in standardised dGEMRIC z-
scores between baseline and 12 months may provide a
more accurate reflection of local changes in cartilage
health at the FAI-relevant chondrolabral junction.
Plain radiograph
All participants will have plain X-rays at baseline and
12 months. At baseline, a supine anterior-posterior (AP)
pelvis, 45-degree modified Dunn view and false profile
view X-ray will be acquired. At 12 months, a supine AP
pelvis and modified Dunn view will be acquired. A
detailed protocol will be provided to radiographers to
ensure consistent patient and X-ray beam positioning
between cases [52]. A comprehensive set of radiographic
measurements applicable to FAI pathoanatomy will be
measured using Hip2Norm software, which has been
validated for this purpose [53]. These measures include:
pelvic orientation, acetabular anteversion, acetabular
depth, acetabular inclination, femoral head coverage,
femoral head sphericity, joint space width, and joint con-
gruity. These data will be reported at baseline and
12 months, enabling characterisation of the effects of
surgery on the pathoanatomy of FAI.
Motion analysis EMG data collection
Participants enrolled in Melbourne will undergo motion
analysis during walking, squatting, and jogging at base-
line and 12 months. A 12-camera Vicon motion capture
system (Vicon, Oxford Metrics, UK) will be used to ac-
quire three-dimensional motion data of participants
wearing a full-body marker set with modified lower limb
10-marker clusters at 120 Hz) [54]. Ground reaction
forces will be acquired using two AMTI (Advanced
Mechanical Technology Institute, Massachusetts, USA)
force plates sampling at 1200 Hz. electromyograms will
be acquired with a Noraxon DTS 2400 wireless telem-
etry system from 14 muscles of the study limb, sampling
at 1200 Hz. According to surface electromyography for
the non-invasive assessment of muscles (SENIAM) guide-
lines [55], surface electrodes will be placed on the soleus,
medial and lateral gastroncnemii, hamstrings, vasti, rectus
femoris, tibialis anterior, peroneals, adductors, tensor fa-
sciae latae, gluteus maximus, and gluteus medius. Bio-
mechanical outcome parameters will include tri-planar
kinematics and kinetics of the lower-limb segments and
joints, and relevant pelvis and trunk kinematics.
Calibrated EMG-informed Neuromusculoskeletal
(CEINMS) [56] and Finite Element Method (FEM)
models will be used to calculate stress and strain fields,
as well as strain energy density, of the acetabular and
Fig. 2 Selection of mid-sagittal plane for dGEMRIC analysis. Selection of the mid-sagittal plane using OsiriX. dGEMRIC analysis will be performed
on the three mid-sagittal slices
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femoral cartilages to determine cartilage loading stimu-
lus at baseline and 12 months [57]. The MRI and gait
analysis data will be employed to create patient-specific
lower-limb rigid body musculoskeletal models and FEM
hip meshes using the Musculoskeletal Atlas Project
(MAP) software [58]. The EMG-informed muscle-tendon
and joint contact forces will be determined using CEINMS
and then applied as force-boundary conditions to a FEM
model of the hip. We will then resolve the stress and
strain distributions in the hip bones and cartilages using
FEBio (febio.org), which is validated, Open-source FEM
software specifically designed for biomechanics appli-
cations [59].
Hip muscle strength assessment
Participants who attend the gait laboratory for motion
analysis will have their hip muscle strength assessed
at baseline and 12 months. A digital dynamometer
force gauge (Sparker Instruments, China) will be used
to assess peak isometric hip flexion, extension, adduc-
tion, and abduction strengths. For each hip strength
assessment, participants will stand upright within a
testing frame with the force transducer secured via a
perpendicular strap around the lower thigh to the
frame (see Fig. 3). The distance from the greater tro-
chanter to the force transducer thigh attachment will
be recorded as the lever arm distance in metres (m).
For the study leg, participants will perform two sub-
maximal efforts for familiarisation. Participants will
then perform two maximal efforts and will be encour-
aged to pull as hard they can for 3–5 s with a short
rest period between each of the two maximal trials.
From the two maximal trials, the peak torque in
Newton metres (Nm) will be determined and normal-
ised to body mass (Nm/kg).
Patient reported outcomes
Patient reported outcomes will be collected at baseline,
6 months, and 12 months, as described in Table 1. The
modified World Health Organisation Health and Work
Performance Questionnaire (WHO HPQ) [38] will be
utilised to assess cost-effectiveness of the interventions.
Changes in participant symptoms and quality of life will
be assessed using the iHOT-33 [39], the HOOS [40–42],
EQ-5D [43] and the SF-12 [44]. A Global Improvement
Scale (GIS) will be used to determine patient perceived
overall improvement at 6 months and 12 months follow-
ing baseline. Patient satisfaction will be measured on a
five-point Likert scale after 12 months, in response to
the questions, “Overall, how satisfied are you with the
treatment you received?” and “Overall, how satisfied are
you with the results of your treatment?”.
Need for further procedures
The need for any further treatments will be recorded for
participants in both arms of the study. Further treat-
ments may include but are not limited to hip arthros-
copy, open hip preservation surgery, hip replacement, or
additional non-protocol physiotherapy. The need for fur-
ther procedures will be ascertained by questionnaire at
two years and three years.
Adverse events
The number and type of adverse events will be recorded
for all participants up to 12 months. Adverse events (AE)
are defined as any untoward medical occurrence in a clin-
ical trial patient and which do not necessarily have a
causal relationship with the treatment. All AEs will be
listed on the appropriate Case Report Form for routine re-
turn to the researchers. Serious adverse events (SAE) are
defined as any untoward and unexpected medical occur-
rence that: results in death; is life-threatening; requires
hospitalisation or prolongation of existing inpatients hos-
pitalisation; results in persistent or significant disability or
Fig. 3 Hip muscle strength assessment. For hip muscle group
strength assessment, participants are instructed to stand upright,
look straight ahead and use the rail for light finger-tip support. Following
familiarisation participants receive strong verbal encouragement to pull
as hard as possible. Two maximal efforts for each hip muscle group
are recorded
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incapacity; is a congenital anomaly or birth defect; or any
other important medical condition which, although not
included in the above, may require medical or surgical
intervention to prevent one of the outcomes listed. All
SAEs will be reported to the ethics committee within 72 h
of the investigators becoming aware of them. All partici-
pants experiencing SAEs will be followed-up as per proto-
col until the end of the trial.
Statistical analysis
Descriptive analysis
Data will be checked for outliers and missing values, and
validated using the defined score ranges for all outcome
measures. Standard statistical summaries (medians,
ranges, means, standard deviations; dependent on the dis-
tribution of the outcome) will be presented for all out-
come measures. Scatter plots depicting the relationship
between relevant outcomes will be presented with corre-
sponding correlation coefficients. Counts with percentages
will be presented for categorical variables. Baseline data
will be summarized to check comparability between treat-
ment arms, and to highlight any systematic differences be-
tween those individuals in the study, those ineligible, and
those eligible but withholding consent. Comparisons in
baseline characteristics for categorical variables will be
based on χ2 test or Fisher’s exact test, if expected cell
counts are small. For continuous variables two-group
comparisons will be performed using t-tests or the Wil-
coxon rank-sum test for non-normal data. Data may not
be available due to voluntary withdrawal of patients, lack
of completion of individual data items or general loss to
follow-up. Where possible the reasons for missing data
will be ascertained and reported. If judged appropriate,
missing data will be imputed using a multiple imputation
strategy. Any imputation methods used for scores and
other derived variables will be carefully considered and
justified, and analysis of imputed datasets used to assess
the sensitivity of the analysis to the missing data.
The primary analysis will be of the change in the
dGEMRIC index score for a combined acetabular and
femoral head cartilage ROI from baseline to 12 months,
with the difference in mean change between the two
treatment groups presented with a 95% confidence inter-
val and compared using an independent samples t-test.
This strategy will also be applied for the standardised
dGEMRIC z-scores. Change in scores for the dGEMRIC
data will be assumed to be normally distributed; possibly
after appropriate variance-stabilising transformation of
the individual time-point scores. Analysis including ad-
justment for baseline dGEMRIC index score and rele-
vant baseline characteristics will be performed using
Analysis of Covariance with the change from baseline
modelled as the dependent variable. This strategy will
also be applied for the dGEMRIC index score of the
separate acetabular and femoral head cartilage ROIs and
the standardized dGEMRIC z-scores.
The above strategy will also be performed for analysis of
other approximately normally distributed secondary out-
come measures including those related to plain radiog-
raphy, MRI, muscle strength, full 3D gait analyses, EMG-
informed NMS and FEM models, and the patient reported
outcomes (iHOT-33, HOOS, EQ-5D and SF-12). Differ-
ences in dichotomous outcome variables such as adverse
events, complications related to the trial interventions and
the need for further procedures will be compared between
groups using chi-squared tests (or Fisher’s exact test). The
temporal patterns of complications and the need for fur-
ther procedures will be presented graphically. If there are
sufficient events cumulative incidence curves of the time
to first procedure (any or a specific type) will be plotted
by treatment group calculated using the Kaplan-Meier
method. Ordinal scores for patient satisfaction will be
compared between intervention groups using proportional
odds logistic regression analysis with the proportional
odds assumption checked. Although our inferences will be
drawn from the intention-to-treat analysis, we will per-
form per protocol analyses to place these in context. We
plan to perform exploratory subgroup analyses by FAI
type and by whether referral to the study was via the pri-
vate or public healthcare systems. We do not anticipate
that crossovers will be a major issue for this study. We,
therefore, expect the main analyses to provide definitive
results. If participant adherence to or completion of the
PHT proves to be more problematic than expected, we
will augment the planned analysis with a complier average
causal effect (CACE) analysis.
Economic analysis
A secondary objective of this study is to assess the cu-
mulative direct and indirect costs associated with each
treatment approach and to calculate the incremental
cost-effectiveness ratio per clinically meaningful change in
cartilage structure (dGEMRIC). The following methods
can be used to assess direct and indirect costs associated
with each treatment arm. Participants will be asked for
consent to researchers linking their study data to various
administrative data sources (state, federal and private
health insurance databases). To assess direct costs, data
on healthcare utilisation over the study period (including
hospital admissions, emergency presentations, primary
care utilisation and pharmaceutical claims records on sub-
sidised prescription medicines) will be extracted for all
consenting participants. Health services and prescription
medications will be costed using market prices for the
most recent financial year [60–62].
Information on indirect costs associated with each
treatment arm will be assessed at baseline, 6 and
12 months using a survey based on the modified World
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Health Organisation Health and Work Performance
Questionnaire (WHO HPQ). The WHO HPQ is a vali-
dated tool [38] designed to assess three domains of work
performance (absenteeism, presenteeism and critical in-
cidents), as well as basic demographic and occupational
information. Participants will be asked to report their
annual pre-tax income. As questions relating to income
are known to have high rates of missing data, partici-
pants will also be asked to report the category of their
main job (e.g. executive, service, labourer). Where an-
nual income data are found to be missing, mean salaries
for each category of employment can be imputed from
the Australian Bureau of Statistics average weekly earn-
ings data [63]. Cost estimates for lost productivity will
be conducted according to previously described methods
[64]. The survey will also include several questions to
capture information on direct costs not obtainable
through data linkage, such as outpatient physiotherapy
in the public sector and non-subsidised over the counter
medication utilisation.
Sample size
Sample size calculations for the primary outcome are
based on statistical power of 90%, and two-sided signifi-
cance of 5% significance level. With a sample size of 54
patients in each group, we expect to detect a difference
of at least 50 ms between two study groups at 12 months
based on a standard deviation (SD) of 80 ms for the
dGEMRIC index [65, 66]. 50 ms was chosen as clinically
significant based upon increased risk of subsequent total
hip replacement [67].
Previous research identified an R2 ≈ 0.2–0.3 between in-
direct external measures of hip joint loading and hip neck
bone density in people with hip OA, when two covariates
(weight and height) were included, indicating a moderate
relationship between biomechanical and structural mea-
sures. We expect higher R2 values, given that we have dir-
ect estimates of cartilage stress and strain. Being
conservative, however, in order to achieve an R2 > 0.2 be-
tween cartilage loading stimulus and dGEMRIC scores
(with three covariates), a power of 90%, and a two-sided
significance level of 5% we require a total of 56 patients at
each site. We will, therefore, aim to recruit a total of 140
participants for the study to allow for a drop-out rate of
20%, including 5% cross over to the surgical group.
Data safety and monitoring
An independent Data Safety and Monitoring Board
(DSMB) will be responsible for oversight of this clinical
trial, including protocol adherence, recruitment, adverse
events, SAEs, treatment side effects and data analysis and
data safety. The members of the DSMB are not involved
in the study, do not have any conflict of interest and will
not benefit in any way from the results of this trial.
Discussion
The need for RCTs to determine the most effective ap-
proach for the management of FAI is well-recognised
[13]. This RCT will compare arthroscopic hip surgery to
PHT for the management of FAI. Strengths of this trial
include the large number of structural, biomechanical,
and patient-reported outcomes by which these two treat-
ments will be compared. Together, these outcomes are
likely to provide insight into the effect of these two man-
agement approaches on the pathogenesis of hip OA, in-
cluding their likely effectiveness for modification of future
hip OA risk. Furthermore, the randomised, pragmatic,
and multicentre nature of this trial will increase the gen-
eralisability of the results. Dissemination of results for
this trial will occur through publication in peer-reviewed
journals and presentation at relevant conferences.
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